Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions. While molecular profiling using DNA-based methods is routine in precision oncology, the incorporation of transcriptomics is not yet well established in the clinic.
In this webinar, Moritz Schütte, head of next-generation sequencing data analysis at Alacris, will explore the advantages of RNA sequencing alone or in combination with whole-exome sequencing as part of a precision oncology workflow.
In addition to discussing how RNA-seq identifies molecular alterations and illuminates the tumor microenvironment, Dr. Schütte will explain how mathematical modeling of molecular data can predict drug sensitivity. Applications will be shown for metastatic melanoma and acute lymphoblastic leukemia.
In this webinar, you will learn:
Offered Free by: Qiagen
See All Resources from: Qiagen
This download should complete shortly. If the resource doesn't automatically download, please, click here.